REG - Tissue Regenix Group - Notice of Results

Tissue RegenixAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA9779Ea&default-theme=true

RNS Number : 9779E  Tissue Regenix Group PLC  01 March 2024

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Notice of full year results

Investor presentation

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
will announce its final results for the year ended 31 December 2023 on Tuesday
19 March 2024.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer,
will host a live online presentation relating to the final results via the
Investor Meet Company platform at 11.00am on Tuesday 19 March 2024. The
presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
(https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor)

 

Investors who already follow Tissue Regenix on the Investor Meet Company
platform will be de facto invited.

 

 

For more information:

 

 Tissue Regenix Group plc                                                www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                                    via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)   Tel: +44 (0)20 7933 8780
 Alice Woodings/Charlotte Edgar      TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDZGZZGLRGDZM